GSK logo

GSK(OTC) GLAXF

Market Cap$98.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1975)+1,158%
5 Year+28%
1 Year+17%
1 Month+4%
$24.53
+4.16%
+0.98Today
GSK last closing stock price
MetricPriceDate
Last closeUSD 24.532026-10-09
GSK stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.73%USD 22.772026-10-02
1 month+4.34%USD 23.512026-09-09
3 month-5.84%USD 26.052026-07-10
Year to date+2.31%USD 23.982025-12-31
1 year+16.88%USD 20.992025-10-09
3 year+47.61%USD 16.622023-10-10
5 year+27.6%USD 19.222021-10-08
Since inception+1,158.01%USD 1.951975-01-06

GSK Financials at a Glance

Market Cap

$98.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£31.16B

Net Income (TTM)

£4.34B

EPS (TTM)

$1.59

P/E Ratio

15.23

Dividend

$0.91

Beta (Volatility)

-0.13 (Low)

Price

$24.53

Volume

58

Open

$23.52

Previous Close

$24.53

Daily Range

$22.73 - $24.53

52-Week Range

$20.80 - $31.48

Estimated Earnings Date

Oct 28, 2026

GLAXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GSK

GSK plc is a global healthcare and pharmaceutical leader headquartered in Brentford, United Kingdom. With a rich history dating back to 1715, GSK operates across various international markets, focusing on the research, development, manufacturing, and commercialization of healthcare products.

Products and Services
  • Pharmaceuticals for respiratory health, HIV, oncology, and more
  • Vaccines for various infectious diseases
  • Consumer healthcare products including oral health and wellness items
Growth Outlook
  • Recent quarterly revenue reached £8.41 billion, indicating strong market demand
  • Trailing twelve months (TTM) revenue of £31.5 billion shows consistent growth
  • Strategic partnerships enhance innovation and expand product offerings
Financial Highlights
  • Net income for Q2 2026 was £435 million, reflecting effective cost management
  • TTM dividend yield stands at 3.56%, appealing to income-focused investors
  • Operating income margin of 5.7% demonstrates operational efficiency
GSK plc is well-positioned in the healthcare sector, leveraging its extensive portfolio and innovative capabilities. The company's focus on research and development, combined with strategic partnerships, supports its growth trajectory. Recent financial performance highlights, including a significant quarterly revenue and a solid net income, underscore the company's operational strength. The attractive dividend yield further enhances its appeal to potential investors. GSK's commitment to addressing global health challenges through its diverse product offerings positions it as a key player in the pharmaceutical industry.
AI Generated • Sep 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

66,841

CEO

Luke Miels, MBA

Website

www.gsk.com

Headquarters

London, GL WC1A 1DG, GB

GLAXF Financials

Key Financial Metrics (TTM)

Gross Margin

73.29%

Operating Margin

24.12%

Net Income Margin

14.52%

Return on Equity

28.35%

Return on Capital

21.03%

Return on Assets

7.81%

Earnings Yield

6.57%

Dividend Yield

3.71%

Payout Ratio

55.30%

Stock Overview

Market Cap

$98.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.01B

Volume

58

Avg. Volume

943.677

Financials (TTM)

Gross Profit

£22.85B

Operating Income

£5.71B

EBITDA

£10.05B

Operating Cash Flow

£8.04B

Capital Expenditure

-£1.67B

Free Cash Flow

£6.37B

Cash & ST Invst.

£3.08B

Total Debt

£18.11B

GSK Performance Analysis

GSK annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 36,120,722,0046.3%
20232023-12-31GBP 37,699,276,2674.4%
20242024-12-31GBP 40,092,639,0696.3%
20252025-12-31GBP 43,051,521,1527.4%
GSK sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-28-18.6%
Q42025-12-3132.5%
Q12026-03-31-11.5%
Q22026-06-3010.2%
GSK annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 4.51142.5%
20232023-12-31GBP 1.49-67.0%
20242024-12-31GBP 0.79-46.7%
20252025-12-31GBP 1.83130.3%
GSK sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-285.7%
Q42025-12-31-56.8%
Q12026-03-31168.8%
Q22026-06-30-74.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£8.41B

+5.3%

Gross Profit

£6.34B

+8.9%

Gross Margin

75.36%

N/A

Market Cap

$98.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.47M

N/A

Employees

66,841

N/A

Net Income

£435.00M

-69.9%

EBITDA

£2.60B

-19.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£3.08B

-14.8%

Total Debt

£18.11B

-24.0%

Accounts Receivable

£8.02B

+9.5%

Inventory

£6.24B

+2.7%

Long Term Debt

£13.85B

-34.1%

Short Term Debt

£4.26B

+51.4%

Return on Assets

7.81%

N/A

Return on Invested Capital

19.92%

N/A

Free Cash Flow

£2.18B

+49.2%

Operating Cash Flow

£2.51B

+19.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PFEPfizer Inc.
$28.40+0.42%
AZN.LAstraZeneca PLC
£120.26+0.23%
AMGNAmgen Inc.
$417.57+0.65%
JNJJohnson & Johnson
$263.73+0.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.67-0.89%
INTCIntel
$101.35-3.20%
NOKNokia
$9.90-4.44%
NVDANvidia
$226.32-1.29%

Questions About GLAXF

What is the current price of GSK?

GSK is trading at $24.53 per share.

What is the 52-week range for GSK?

Over the past 52 weeks, GSK has traded between $20.80 and $31.48.

How much debt does GSK have?

As of the most recent reporting period, GSK reported total debt of £24.21B.

How much cash does GSK have on hand?

GSK reported £4.12B in cash and cash equivalents in its most recent financial results.

What is GSK’s dividend yield?

GSK currently has a dividend yield of 3.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services